SpineSmith hires new vice-president of R&D
This article was originally published in Clinica
Executive Summary
In a bid to strengthen its position in adult stem cell technologies, SpineSmith Partners has appointed Brian Burkinshaw vice-president of R&D. Mr Burkinshaw has over 30 years' experience, both with traditional orthopaedic companies and emerging biologic firms, which SpineSmith believes will help it develop regenerative medicine products. He has previously worked for Spinal Restoration, LDR Spine and Zimmer, as well as venture capital firm Path4 Ventures. SpineSmith (Austin, Texas), along with its subsidiary Celling Technologies, plans to launch two new regenerative products "in the coming months". SpineSmith develops implants and biologics for surgical fixation, correction and regeneration of the spine, while Celling is focused on autologous adult stem cell therapies.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.